Nerve Block Extends Nerve Function Recovery in Patients with Diabetic Foot Ulcers

J Pain Res. 2024 Nov 22:17:3949-3957. doi: 10.2147/JPR.S491539. eCollection 2024.

Abstract

Objective: Research has revealed that patients with diabetes and peripheral neuropathy exhibit significantly elevated nerve stimulation thresholds. However, the minimum stimulation thresholds of peripheral nerves in patients with diabetic foot, along with the recovery of nerve function, remain undetermined. The aim of this study is to investigate the minimum stimulation thresholds of the femoral and sciatic nerves, as well as the duration of nerve block, in patients diagnosed with diabetic foot.

Methods: From July 2020 to March 2022, a prospective study was conducted involving patients aged 50-80 scheduled for distal lower limb surgery. The study included 83 patients with diabetic foot and 48 individuals without diabetes. Prior to surgery, an ultrasound-guided approach combined with nerve stimulation was employed to administer a popliteal sciatic nerve block (20 mL of ropivacaine 5 mg/mL) and a femoral nerve block (20 mL of ropivacaine 5 mg/mL). During the ultrasound-guided femoral and popliteal sciatic nerve blocks, the electric current required to elicit motor activity in both the femoral and popliteal sciatic nerves was assessed.

Results: The study revealed that patients with diabetic foot exhibited significantly higher stimulation thresholds for femoral and sciatic nerve blocks, as well as a substantially longer duration of femoral and sciatic sensory and motor blocks (P < 0.01). Additionally, nerve injury was observed in 4 patients (4.8%) within the diabetes mellitus (DM) group.

Conclusion: Patients with diabetic foot exhibit higher minimum stimulus thresholds for the femoral and sciatic nerves and experience delayed recovery from ropivacaine block.

Keywords: diabetic foot; minimal stimulation threshold; nerve blocks; nerve damage; ultrasound.

Grants and funding

This study was funded by Guangxi Natural Science Foundation, grant numbers 2020GXNSFDA238025; National Key 230 R&D Program, grant numbers (2018YFC2001905); Guangxi Health Commission (Z20210015); Beijing Medical Award Foundation (YXJL-2021-0307-0467); Guangxi Medical and health appropriate technology development and promotion Foundation (S2020021).